Prognostic significance of etiological risk factors in early breast cancer

Breast Cancer Research and Treatment

Volumn 43, Issue 3, 1997, Pages 217-223

  Schouten, Leo J ^a,b,c   Hupperets, Pierre S G J ^d   Jager, Jos J ^a,e   Volovics, Lex ^f   Wils, Jacques A ^g   Verbeek, André L M ^b,c   Blijham, Geert H ^h  

^a Maastricht UMC+ Comprehensive Cancer Centre   (Netherlands)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

^c Integraal Kankercentrum Oost   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e Inst for Radiation Oncology Limburg   (Netherlands)

^f MAASTRICHT UNIVERSITY   (Netherlands)

^g LAURENTIUS HOSPITAL   (Netherlands)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Age at first full term pregnancy; Breast cancer; Etiological risk factors; Family history; Oral contraceptives; Prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SURVIVAL; FAMILY HISTORY; FEMALE; HUMAN; LYMPH NODE METASTASIS; MENARCHE; MENOPAUSE; NONBIOLOGICAL MODEL; PARITY; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR;

EID: 0031002478     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005790531122     Document Type: Article

References (38)

1. Kelsey JL: Breast cancer epidemiology: Summary and future directions. Epidemiol Rev 15 (1): 256-263, 1993
2. Bernstein L, Ross RK: Endogenous hormones and breast cancer risk. Epidemiol Rev 15 (1): 48-65, 1993
3. Goodwin PJ, Boyd NF: Body size and breast cancer prognosis: a critical review of the literature. Breast Cancer Res Treat 16: 205-214, 1990
4. Juret P, Couette JE, Mandard AM, Carré A, Delozier T, Brune D, Vernhes JC: Age at menarche as a prognostic factor in human breast cancer. Eur J Cancer 12: 701-704, 1976
5. Papatestas AE, Mulhivill N, Jose C, Ioannovich J, Lesnick G, Aufses AH: Parity and prognosis in breast cancer. Cancer 45: 191-194, 1980
6. Korzeniowski S, Dyba T: Reproductive history and prognosis in patients with operable breast cancer. Cancer 74: 1591-1594, 1994
7. Greenburg ER, Vessey MP, McPherson K, Doll R, Yeates D: Body size and survival in premenopausal breast cancer. Br J Cancer 51: 691-697, 1985
8. Rosner D, Lane WW: Oral conceptive use has no adverse effect on the prognosis of breast cancer. Cancer 57: 591-596, 1986
9. Ewertz M, Gillanders S, Meyer L, Zedeller K: Survival of breast cancer patients in relation to factors which affect the risk of developing breast cancer. Int J Cancer 49: 526-530, 1991
10. Holmberg L, Lund E, Bergström R, Adami HO, Meirik O: Oral contraceptives and prognosis in breast cancer: effect of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer 30A: 351-354, 1994
11. Schönborn I, Nischan P, Ebeling K: Oral contraceptive use and the prognosis of breast cancer. Breast Cancer Res Treat 30: 283-292, 1994
12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 347: 1713-1727, 1996
13. Hupperets PSGJ, Wils J, Volovics L, Schouten L, Fickers M, Bron H, Schouten HC, Jager J, Smeets J, de Jong J, Blijham GH: Adjuvant chemohormonal therapy with cyclophosphamide, doxyrubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive breast cancer patients. Annals of Oncology 4: 295-301, 1993
14. UICC: TNM Classification of Malignant Tumours (edition 3). International Union against Cancer, Geneva, 1978
15. Cox DR, Oakes D: Analysis of Survival Data. Chapman and Hall, London, 1984
16. SAS® Technical Report P-229. SAS/STAT® Software: Changes and Enhancement. Release 6.07. SAS® Institute Inc. Cary (NC, USA), 1992, pp 433-480
17. Morrison AS, Lowe CR, MacMahon B, Ravnihar B, Yuaza S: Incidence risk factors and survival in breast cancer: Report on five years of follow-up observation. Eur J Cancer 13: 209-214, 1977
18. Mohle-Boetani JC, Grosser S, Whittemore AS, Malee M, Kampert JB, Paffenbarger RS: Body size, reproductive factors, and breast cancer survival. Prev Med 17: 634-642, 1988
19. Caleffi M, Fentiman IS, Birkhead BG: Factors at presentation influencing the prognosis in breast cancer. Eur J Cancer Clin Oncol 25: 51-56, 1989
20. Lees AW, Jenkins HJ, May CL, Cherian G, Lam EHW, Hanson J: Risk factors and 10-year breast cancer survival in Northern Alberta. Breast Cancer Res Treat 13: 143-151, 1989
21. De Waard F, Vd Velden JW, De Does M: The influence of the relative body weight on the prognosis of breast cancer in women (in Dutch). Ned Tijdschr Geneesk 129: 454-459, 1985
22. Black MM, Hankey BF, Barclay THC: Parity as a prognostic factor in young breast cancer patients. J Natl Cancer Inst 70: 27-30, 1983
23. Wang DY, Rubens RD, Allen DS, Millis RR, Bulbrook RD, Chaudary MA, Hayward JL: Influence of reproductive history on age at diagnosis of breast cancer and prognosis. Int J Cancer 32: 427-432, 1985
24. Kyogoku S, Hirohata S, Takeshita S, Nomura Y, Shigematsu T, Horie A: Survival of breast-cancer patients and body size indicators. Int J Cancer 46: 824-831, 1990
25. Moore FD, Woodrow SI, Aliapoulios MA, Wilson RE: Carcinoma of the breast. A decade of new results with old concepts. New Engl J Med 277 (6): 293-296, 1967
26. Leis HP, Black MM, Sall S: The pill and the breast. J Reprod Med 16 (1): 5-9, 1976
27. Spencer JD, Millis RR, Hayward JL: Contraceptive steroids and breast cancer. Br Med J i: 1024-1026, 1978
28. Vessey M, Baron J, Doll R, McPherson K, Yeates D: Oral contraceptives and breast cancer: Final report of an epidemiological study. Br J Cancer 43: 455-462, 1983
29. Rosner D, Lane WW, Brett RP: Influence of oral contraceptives on the prognosis of breast cancer in young women. Cancer 55: 1556-1562, 1985
30. Rosner DH, Joy JV, Lane WW: Oral contraceptives and prognosis of breast cancer in women aged 35 to 50. J Surg Oncol 30: 52-59, 1985
31. Olsson H, Möller TR, Ranstam J, Borg Å, Fernö M: Early oral contraceptive use as a prognostic factor in breast cancer. Anticancer Res 8: 29-32, 1988
32. Ranstam J, Olsson H, Garne JP, Aspegren K, Janzon L: Survival in breast cancer and age at start of oral contraceptive usage. Anticancer Res 11: 2043-2046, 1991
33. Millard FC, Bliss JM, Chilvers CED, Gazet JC: Oral contraceptives and survival in breast cancer. Br J Cancer 56: 377-378, 1987
34. Lynch HT, Albano WA, Recabaren JA, Fain PR, Lynch PM: Survival in hereditary breast and colon cancer. JAMA 246: 1197, 1981
35. Slattery ML, Berry TB, Kerber RA: Is survival among women diagnosed with breast cancer influenced by family history of breast cancer? Epidemiology 4: 543-548, 1993
36. Anderson DE, Badzioch MD: Survival in familial breast cancer patients. Cancer 58: 360-365, 1986
37. Ruder AM, Moodie PF, Nelson NA, Choi NW: Does family history of breast cancer improve survival among patients with breast cancer? Am J Obstet Gynecol 158: 963-968, 1988
38. Schoenfeld DA: Sample-size formula for the proportional-hazards regression model. Biometrics 49: 499-503, 1983